Legal & General Group Plc Buys New Shares in Dianthus Therapeutics, Inc. $DNTH

Legal & General Group Plc bought a new stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 32,331 shares of the company's stock, valued at approximately $3,152,000. Legal & General Group Plc owned about 0.06% of Dianthus Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DNTH. The Manufacturers Life Insurance Company purchased a new position in shares of Dianthus Therapeutics in the second quarter valued at $6,125,000. Spruce Street Capital LP purchased a new position in Dianthus Therapeutics in the 2nd quarter valued at about $34,587,464. Elevation Point Wealth Partners LLC acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $868,000. Quantbot Technologies LP acquired a new stake in shares of Dianthus Therapeutics during the second quarter valued at about $174,000. Finally, Emerald Investment Advisers LLC purchased a new stake in shares of Dianthus Therapeutics during the second quarter worth about $2,579,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

Shares of DNTH stock opened at $108.10 on Friday. Dianthus Therapeutics, Inc. has a 1 year low of $24.49 and a 1 year high of $117.88. The business's fifty day moving average is $105.23 and its 200-day moving average is $89.08. The stock has a market cap of $5.91 billion, a PE ratio of -26.05 and a beta of 1.24.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The firm had revenue of $0.76 million during the quarter, compared to analyst estimates of $0.30 million. Equities research analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current year.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 30,000 shares of the firm's stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $80.80, for a total transaction of $2,424,000.00. Following the completion of the sale, the senior vice president directly owned 30,000 shares in the company, valued at approximately $2,424,000. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Anne McGeorge sold 7,750 shares of the company's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the transaction, the director owned 1,250 shares in the company, valued at approximately $136,262.50. This represents a 86.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 283,678 shares of company stock worth $29,672,400 in the last three months. Insiders own 3.02% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on DNTH shares. Truist Financial increased their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a "buy" rating in a report on Thursday, August 6th. Wedbush increased their target price on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an "outperform" rating in a report on Wednesday, August 5th. Citigroup initiated coverage on shares of Dianthus Therapeutics in a report on Friday. They issued a "buy" rating and a $156.00 target price on the stock. Wall Street Zen upgraded Dianthus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Guggenheim restated a "buy" rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $126.92.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

Want to see what other hedge funds are holding DNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source